Observational analysis identifies metabolites and microbiota linked to CAR-T therapy outcomes in myeloma, indicating potential for personalized treatment.
Key Points
Succinate was associated with CAR T-cell persistence and phenotypes, and metabolic profiles significantly correlated with treatment efficacy.
Specific gut microbiota like Acidaminococcaceae showed associations with clinical outcomes in CAR-T therapy for myeloma patients.
This analysis utilized murine myeloma models to demonstrate the impacts of diet on CAR T-cell functionality and tumor control.
Integrated models indicate microbial and metabolic factors could enhance risk assessment for myeloma patients undergoing CAR-T therapy.
Cite This Study
Uribe‐Herranz et al. (2025) studied this question.